A phase IIa study of Zimura® (avacincaptad pegol) in combination with anti-VEGF therapy for wet age-related macular degeneration (AMD)

Trial Profile

A phase IIa study of Zimura® (avacincaptad pegol) in combination with anti-VEGF therapy for wet age-related macular degeneration (AMD)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs Avacincaptad pegol (Primary) ; Ranibizumab (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Sep 2017 Status changed from planning to recruiting, according to an OphthoTech Corporation media release.
    • 31 Jul 2017 New trial record
    • 26 Jul 2017 According to an OphthoTech Corporation media release, this trial is scheduled to start by the end of this year.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top